U.S. Markets open in 8 hrs 21 mins

Breakfast Technical Briefing on Neptune Technologies & Bioressources and Three Other Additional Biotech Stocks

Stock Research Monitor: MGTA, MTNB, and MYOK

LONDON, UK / ACCESSWIRE / July 25, 2018 / If you want a free Stock Review on NEPT sign up now at www.wallstequities.com/registration. WallStEquities.com revisits the Biotechnology space, which uses biological processes in the development or manufacture of a product or in the technological solution to a problem. Biotech has a wide range of uses, including food alterations, genetic research and cloning, human and animal health care, pharmaceuticals, and the environment. Under evaluation this morning are the following equities: Magenta Therapeutics Inc. (MGTA), Matinas BioPharma Holdings Inc. (NYSE AMER: MTNB), MyoKardia Inc. (NASDAQ: MYOK), and Neptune Technologies & Bioressources Inc. (NASDAQ: NEPT). All you have to do is sign up today for this free limited time offer by clicking the link below.


Magenta Therapeutics

Cambridge, Massachusetts-based Magenta Therapeutics Inc.’s shares gained slightly by 0.35%, closing Tuesday’s trading session at $14.16. The stock recorded a trading volume of 67,342 shares. Shares of the Company, which engages in developing medicines to bring the curative power of bone marrow transplant to patients, are trading 4.36% above their 50-day moving average.

On July 16th, 2018, research firm Wedbush initiated an 'Outperform' rating on the Company's stock, with a target price of $22 per share. Get the full research report on MGTA for free by clicking below at:


Matinas BioPharma Holdings

On Tuesday, shares in Bedminster, New Jersey-based Matinas BioPharma Holdings Inc. recorded a trading volume of 73,169 shares. The stock dropped 2.40%, ending the day at $0.39. The Company’s shares are trading below their 50-day moving average by 20.97%. Furthermore, shares of Matinas BioPharma, which focuses on the discovery and development of various product candidates, have an RSI of 43.82.

On July 09th, 2018, Matinas BioPharma (MTNB) and the National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health (NIH), announced a research collaboration focused on the development of a novel therapy for the treatment of human immunodeficiency virus combining targeted antisense oligonucleotides and MTNB’s LNC delivery technology. This series of studies will be conducted at the NIH in Bethesda, MD, under the direction of Principal Investigator Dr. Nath and Co-Investigator Lisa Henderson, Ph.D. MTNB’s complimentary research coverage is a few simple steps away at:



South San Francisco, California headquartered MyoKardia Inc.’s stock finished the day 0.61% lower at $57.10 with a total trading volume of 298,865 shares. The Company’s shares have advanced 17.85% in the last month, 14.09% in the previous three months, and 302.11% over the past year. The stock is trading above its 50-day and 200-day moving averages by 13.71% and 21.57%, respectively. Additionally, shares of MyoKardia, which discovers, develops, and commercializes therapies for the treatment of rare cardiovascular diseases, have an RSI of 71.81.

On July 10th, 2018, research firm Bank of America/ Merrill initiated a 'Buy' rating on the Company's stock, with a target price of $71 per share. Register for your free research report on MYOK at:


Neptune Technologies & Bioressources

Shares in Laval, Canada headquartered Neptune Technologies & Bioressources Inc. ended yesterday’s session 0.70% lower at $2.82. The stock recorded a trading volume of 596,139 shares. The Company’s shares have surged 246.01% over the past year. The stock is trading 15.15% above its 200-day moving average. Moreover, shares of the Company, which produces and commercializes nutraceutical products and turnkey solutions primarily for omega-3 softgel capsules and liquids, have an RSI of 42.67.Wall St. Equities’ downloadable research report on NEPT available at:


Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit



For any questions, inquiries, or comments reach out to us directly. If you’re a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com

Phone number: 21 32 044 483

Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities